ZyVersa Therapeutics, Inc.
ZVSA
$0.1221
-$0.0079-6.08%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 62.02% | 90.94% | 90.42% | 76.20% | 75.86% |
| Total Depreciation and Amortization | -158.65% | -133.65% | -108.65% | -184.27% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -93.81% | -99.12% | -98.94% | -83.03% | -83.17% |
| Change in Net Operating Assets | 914.46% | 23.54% | -64.24% | -108.01% | -104.96% |
| Cash from Operations | 45.16% | 29.75% | 13.32% | 6.38% | -2.37% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -45.35% | -73.02% | -65.72% | -39.64% | -2.51% |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | 100.00% | 97.80% |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 203.61% | 69.22% | 75.73% | 53.82% | 24.25% |
| Cash from Financing | -45.03% | -40.75% | -0.06% | 261.16% | 1,764.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.59% | -155.87% | 41.88% | 80.90% | 98.74% |